BackFennec Pharmaceuticals Overview
Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Target Price

See Fennec Pharmaceuticals's analyst price targets ($16) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$12.45

Average Target Price

$16.0028.5% upside

2 analysts in the last 4 months

High: $16 | Low: $16

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-12Wedbush$1628.5% upsideOpen
2026-05-22H.C. Wainwright$1628.5% upsideOpen
2026-01-08Piper Sandler$1844.6% upsideOpen
2025-08-15Craig-HallumChase Knickerbocker$1412.4% upsideOpen
2024-05-15Craig-HallumChase Knickerbocker$1736.5% upsideOpen
2024-05-15H.C. WainwrightRaghuram Selvaraju$1520.5% upsideOpen
2024-04-04H.C. WainwrightRaghuram Selvaraju$1844.6% upsideOpen
2024-03-19Craig-HallumChase Knickerbocker$1844.6% upsideOpen
2022-11-22Cantor Fitzgerald$123.6% downsideOpen
2022-09-26Wedbush$1952.6% upsideOpen

Fennec Pharmaceuticals (FENC) FAQ

Fennec Pharmaceuticals's target price stands at $16. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $16 for FENC implies 28.5% upside versus today's price ($12.45). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Fennec Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places FENC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Fennec Pharmaceuticals's reading of $16 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.